Iovance Biotherapeutics faces securities lawsuit
Analysis based on 8 articles · First reported May 18, 2025 · Last updated Jun 12, 2025
The market is negatively impacted by the significant decline in Atara Biotherapeutics' stock price, reflecting investor concern over the company's reduced revenue guidance and alleged misleading statements. This event highlights the risks associated with investing in biotechnology companies and the importance of transparent financial reporting.
Faruqi & Faruqi, LLP is investigating Atara Biotherapeutics, Inc. for alleged violations of federal securities laws. The lawsuit claims that Atara Biotherapeutics made false and misleading statements regarding its growth potential and its ability to generate and drive demand for its treatments, specifically Amtagvi, through its network of approved treatment centers. These alleged misrepresentations led to a dramatic decline in Atara Biotherapeutics' stock price, falling by approximately 44.795% on May 9, 2025, after the company announced reduced revenue guidance for fiscal years 2024 and 2025. James Wilson, a partner at Faruqi & Faruqi, LLP, is encouraging investors who suffered losses to contact the firm to discuss their legal rights and the July 14, 2025 deadline to seek the role of lead plaintiff in the federal securities class action.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard